Nektar Therapeutics (NKTR) Earnings Call Transcript & Summary
March 4, 2024
Earnings Call Speaker Segments
Vivian Wu
executiveThanks, Crystal, and good afternoon to all of you. We appreciate your participation today. Joining us are Howard Robin, who serves as our President and CEO; Dr. Jonathan Zalevsky, our Chief of Research and Development; Dr. Mary Tagliaferri, our Chief Medical Officer; Sandra Gardiner, our Chief Financial Officer; and Jennifer Ruddock, our Chief Business Officer. During this call, we anticipate delivering forward-looking statements about our business, covering topics such as the therapeutic potential of and future development plans for drug candidates and research programs, when clinical studies will begin and when clinical data for drug candidates will become available, the timing of and plans for upcoming clinical data presentations, the establishment and future development plans or success of our collaboration agreement, expectations following our corporate restructuring and reorganization, financial guidance, and other statements concerning the future of our business. Since forward-looking statements concern the future, they carry uncertainties and risks that are hard to predict, and many of those lie beyond our control. Our actual results could differ materially from these statements. Key risks and uncertainties appear in our Form 10-Q filed on November 8, 2023, which you can find at sec.gov. We assume no obligation to update any of these forward-looking statements, whether because of new information, future developments or otherwise. A webcast of this call will be accessible on the IR page of Nektar's website at nektar.com. Having said that, I'd like to turn the call over to our President and CEO, Howard Robin. Howard?
Howard Robin
executiveThanks, Vivian, and I appreciate everyone being here today. For Nektar, 2023 marked a turning point. We narrowed the company's development pipeline to focus on immunology and inflammation, with our main near-term objective being to move REZPEG forward to media data catalysts during the first half of 2025. In the biologic treatment landscape for atopic dermatitis, REZPEG is positioned to be highly disruptive, since it offers a novel agonistic mechanism. The way REZPEG is designed, it both dampens the inflammatory response and, at the same time, restores immune balance by directly expanding functional Treg cells and engaging multiple immunoregulatory pathways in patients who have atopic dermatitis and other autoimmune disorders. Thanks to this unique mechanism, REZPEG could also give patients superior efficacy along with more favorable in frequent dosing. More than 30 million people in the U.S. by itself are fighting this chronic skin condition, and for these patients it can heavily affect quality of life and mental health. During 2023 we achieved meaningful progress on our REZPEG program. Most notably, we got back the full right to REZPEG from Eli Lilly, and we now own the program 100% with no encumbrances. We then moved quickly to design a Phase IIb study in atopic dermatitis, drawing on the promising results from the Phase Ib placebo-controlled randomized study of REZPEG, which demonstrated an 83% drop in eczema skin scores following only 12 weeks of treatment. Our Phase IIb global study in this indication launched in October of '23, and enrollment remains on track for data readout in the first half of '25. In late 2023, we also started work designing a Phase IIb study in alopecia areata, an area of high unmet need. That study begins this month. Roughly 7 million patients in the United States and 160 million people worldwide suffer from alopecia areata. For alopecia patients, JAK inhibitors are the main treatment option, yet they carry a significant rebound effect when treatment ceases and several black box warnings. Given the data we've generated so far on REZPEG in the skin-related autoimmune condition of atopic dermatitis, psoriasis and in patients with cutaneous manifestations of lupus, we believe REZPEG has strong scientific rationale; in the setting of alopecia, it could potentially be a highly differentiated treatment option with a similar remittive effect for this unserved patient population. As I said before, we look forward to the Phase IIb data for our atopic dermatitis study and for our alopecia study in the first half of 2025. For Nektar, these will be highly meaningful data catalysts. Beyond REZPEG, we have another important immunology program that we're advancing toward the clinic. It's a first-in-class differentiated mechanism in immunology, a TNFR2 agonist antibody, NKTR-0165. Research has demonstrated that TNFR2 can boost Tregs' suppressive activity and their general functional characteristics, and this initiative draws on insights gained from our extensive work with REZPEG and within the Treg space, offering a promising approach for addressing autoimmune conditions such as multiple sclerosis and ulcerative colitis. At present, we are running IND-enabling studies, aiming to file an IND during the first half of next year; consistent with our goals for moving our immunology pipeline forward, we shared today a $30 million financing that strengthens Nektar's financial standing further as we approach transformative data catalysts. On an informal note, we are happy to welcome a new, high-quality, long-term investor, TCG Crossover, which plainly shares our confidence in what REZPEG can achieve. Priced at $1.20 per share, this transaction amounts to a premium exceeding 80% relative to Nektar's 30-day VWAP. This leaves us financially strong and stretches our cash runway beyond our earlier guidance—previously the middle of 2026—to now well into the third quarter of 2026. With that, I'll turn the call over to JZ for an R&D discussion. JZ?
Jonathan Zalevsky
executiveThanks, Howard. We'll kick things off today by discussing REZPEG, the most advanced Treg mechanism based on IL-2 in this whole space. Looking across all the REZPEG trials run so far, what we've seen is a clinical pharmacology profile that's consistent and extremely predictable when it comes to engaging the target, plus the peak and how long Treg mobilization lasts. It's shown a safety profile that's well tolerated along with obvious clinical efficacy in atopic dermatitis, and in psoriasis too, as well as in patients who have cutaneous manifestations of lupus. All the deep experience we've built with REZPEG so far throughout this entire clinical program gives us confidence in our ongoing Phase IIb trials in atopic dermatitis and alopecia areata. When it comes to atopic dermatitis specifically, there are 3 key issues that people living with this disease keep facing. First, better efficacy is needed — particularly a greater depth of response and treatment that works quickly. Second, patients want responses that last and remission without therapy. As soon as current therapies stop, patients bounce back fast; and third, there's a shortage of treatments with favorable safety profiles. That matters a lot given how chronic this disease is and the need for dosing that continues. We think there are significant opportunities in this disease state, but what could potentially address them is REZPEG's differentiated profile. Digging into our atopic dermatitis data, throughout the 12-week induction period, REZPEG showed dose-dependent efficacy on both physician-assessed and patient-reported efficacy measures, hitting statistical significance on many of those measures. At the top dose level, REZPEG showed a very rapid onset of response, with more than 40% of patients reaching EASI-75 by week 3, after just 2 doses of REZPEG; that speed of action rivals JAK inhibitors, which have beaten dupilumab on this parameter. At the close of the 12-week induction period, we saw a profound magnitude of efficacy. An 83% reduction in percent change from baseline EASI score at the highest dose tested; that's the largest magnitude of change we've seen for a biologic and outside of one JAK inhibitor. Importantly, we're encouraged by the extended durability seen with REZPEG. Well after the 12-week induction period wraps up, many patients keep durable disease control for another 36 weeks after dosing ends; and this kind of extended disease control following the end of dosing isn't seen with dupilumab or with JAK inhibitors. Durability of the EASI-75 response was preserved, with roughly 70% of EASI-75 responders holding onto that response for 36 weeks after the 12-week induction period ended. That's a very exciting result and suggests REZPEG could potentially be the first remitted therapy for atopic dermatitis; for both patient-reported outcomes and physician-assessed endpoints, we saw the same trends — rapid onset of effect, dose dependence and long durability of control. On top of that, REZPEG was well tolerated, and treatment with REZPEG didn't induce antidrug antibodies in patients, which has been reported with some examples of the IL-2 mutein class. The data we've seen are encouraging, and both our team and KOLs feel a lot of excitement about what REZPEG could offer in atopic dermatitis — specifically, the possibility of long-lasting responses along with infrequent dosing for maintenance. Back in October 2023, we kicked off the Phase IIb trial of REZPEG in atopic dermatitis patients who had not previously been on biologics, and we're making solid progress with enrollment. We're aiming to bring in approximately 400 patients, testing 3 distinct REZPEG regimens against placebo, with assessment taking place across a 16-week induction phase. Once that induction phase wraps up, those patients who hit a threshold allowing them to move from induction into maintenance will be rerandomized into 1 of 2 primary regimens, each at a different dosage, administered either once a month or once every 3 months. That dosing schedule then runs for an additional 28 weeks. Enrollment for this trial remains on track, and we anticipate having data during the first half of 2025. Turning to alopecia areata — we feel REZPEG has a compelling scientific rationale for this condition. Alopecia areata is likewise a skin disease, one in which the immune system begins attacking the hair follicle, which diminishes the capacity of stem cells to produce hair. When the immune attack persists over time, it ultimately causes the hair follicle to release the hair entirely, resulting in patchy hair loss that advances toward balding as the disease worsens. From a biological standpoint, REZPEG, acting through its central mechanism of Treg rescue, is uniquely positioned to tackle the range of immunopathology involved, giving it broad potential to target multiple dermal conditions, alopecia included. Take alopecia, for instance — normal hair follicles contain virtually no immune cells. That means the hair follicle qualifies as an immune privileged tissue. Tregs play a crucial role in preserving that immune privilege, and individuals with alopecia areata experience a collapse of that privileged state. Our view is that REZPEG's Treg mechanism is capable of restoring immune privilege and might deliver durable disease control, something we'd consider game-changing for this indication. JAK inhibitors remain the sole approved agents for alopecia, and they fail to deliver disease durability once a patient stops treatment. On JAK inhibitors, getting a patient's hair to grow back could take anywhere from 9 to 18 months. And as soon as the patient discontinues the JAK inhibitor — which can occur for many reasons, toxicity among them — their hair rapidly sheds again. This patient population has a significant unmet need for tolerable treatment options that deliver durable response, and we believe achieving durability hinges on restoring immune privilege. Given all this, we see an opportunity for REZPEG to emerge as a novel biologic therapy in alopecia areata. This month, we are launching a Phase IIb trial of REZPEG in alopecia. That Phase IIb trial intends to enroll approximately 80 patients with severe to very severe alopecia, who will be randomized between REZPEG and placebo. Treatment will last for 36 weeks, with observation extending to 60 weeks overall. The main measure we're evaluating in this trial is the average percentage change in SALT — that's the Severity of Alopecia Tool — at week 36, and that's the accepted efficacy endpoint regulators use when deciding on approval. Beyond that, we'll be examining several additional secondary endpoints, among them the share of patients experiencing a decrease in SALT. Let me shift over to NKTR-0165, which is our antibody that acts as a TNFR2 agonist. You find TNFR2 expressed at high levels on Tregs, myeloid suppressor cells, regulatory B cells, neuronal cells, and various other cell types, and agonism at TNFR2 has been demonstrated to produce a suppressive impact across the overall functional characteristics of Tregs along with these other suppressive cell populations. When TNFR2 is missing, that's tied to autoimmunity as well as other genetic disorders that look like FOXP3 loss of function. On the other hand, having it present correlates with immunoregulatory activity and protective benefits across numerous cell populations and tissues throughout the body. This agonist program targeting TNFR2 within our pipeline rests on a great deal of Treg knowledge we accumulated through REZPEG. As an illustration, it's established that central Tregs — biomic Tregs being one example — need a meaningful JAK/STAT signal, which the IL-2 receptor pathway supplies under physiological conditions. That's a key element underlying how REZPEG works. By contrast, consider Tregs that depart the central compartment and make their way into distal organs and tissues.
Jonathan Zalevsky
executiveTheir suppressive function upkeep relies less on JAK/STAT signaling, and they instead move that reliance toward engagement of the NF-kB pathway. Among TNF superfamily members expressed on Tregs, TNFR2 shows up in the greatest abundance and serves as the primary force behind NF-kB signaling within those cells; as a result, having a genuine TNFR2 agonist in our pipeline would be an extremely thrilling addition. Indications that TNFR2 agonism might target include multiple sclerosis, mucosal immunology conditions such as ulcerative colitis of the GI tract or other oral mucosal diseases, and even dermal autoimmune diseases like Vitilago. Through an antibody discovery effort based on artificial intelligence conducted with our partner, Biolojic Design, we have pinpointed several lead TNFR2 antibody programs. NKTR-0165 is what the lead antibody is called, and its properties are highly desirable, encompassing exclusive selectivity for TNFR2, agonism of TNFR2 in primary human cells, activity across multiple preclinical efficacy models, and a profile that was very well tolerated in an early non-GLP toxicology study; for this lead, we have created a manufacturing cell line and are carrying out upstream and downstream process development, with the goal of entering the clinic for this program during the first half of 2025. We intend to present the first preclinical data on NKTR-0165 later this year at an upcoming medical conference. As our IND-enabling studies proceed, interest keeps growing in a novel selective TNFR2 agonist such as NKTR-0165, so we continue to welcome the chance to collaborate with companies that share interest in these areas, strategizing on the optimal path forward. Let's now pivot to NKTR-255, our IL-15-based oncology program. NKTR-255 works through an IL-15-based mechanism of action and carries substantial promise as a combination agent alongside cell therapies and other mechanisms like checkpoint inhibitors. For this drug candidate's continued development, we are investigating the most promising partnering routes. Our NKTR-sponsored trial pairing NKTR-255 with the approved CD19 CAR-T therapies BREYANZI and YESCARTA to treat patients who have a large B cell lymphoma has enrolled 15 patients into the dose escalation portion of the study. A separate investigator-sponsored trial at Fred Hutch is also examining the combination of NKTR-255 and BREYANZI; we aim for potential submission of data from these studies at medical meetings during the second half of this year. A clinical trial in non-small cell lung cancer, sponsored and funded by Abel Zeta data, which assesses the combination of Abel Zeta's tumor-infiltrating lymphocyte cell therapy plus NKTR-255 and a checkpoint inhibitor, is likewise ongoing and enrolling patients. Additionally, alongside our partner Merck KGaA, we have been evaluating NKTR-255 combined with BAVENCIO versus single agent MCO in the Phase II JAVELIN Bladder Medley Study. That study remains on track to potentially report interim PFS data later this year. With that, I will hand the call over to Sandy for a review of our financial guidance. Sandy?
Sandra Gardiner
executiveThanks, JZ, and good afternoon to all of you. We closed out the year sitting in a really solid financial spot, holding $329.4 million across cash and investments, and carrying no debt whatsoever on the balance sheet. Like Howard mentioned before, the $30 million financing we announced today makes our cash position even stronger. Revenue came in at $23.9 million for Q4 of 2023, and $90.1 million across the whole of 2023. Operating costs and expenses totaled $57.4 million in the fourth quarter of 2023, and $353.8 million for all of 2023. Nonoperating expenses amounted to $8.6 million in Q4 2023, and $12.6 million for the entirety of 2023. The fourth quarter of 2023 carried a noncash charge of $6.1 million, equal to $0.03 per share, tied to reclassifying the foreign currency translation adjustment into income in connection with winding down our India legal entity. Just to remind everyone, we sold the India facility back in December 2022 for roughly $12 million, and the entity's wind down happened during 2023. Net loss for Q4 2023 reached $42.1 million, or $0.22 per share. Across the full year 2023, net loss was $276.1 million, or $1.45 per share. If you set aside $111.8 million in noncash goodwill and other impairment charges, then net loss on a non-GAAP basis for the full year 2023 came to $164.3 million, or $0.86 basic and diluted loss per share. As we look toward 2024 and past it, our financial position stays strong, partly because of the cost savings initiatives we carried out last year; our plan is to finish 2024 holding between $200 million and $225 million in cash and investments. On top of the $30 million pipe announced this morning, our 2024 cash guidance also factors in $15 million coming from an amendment executed today on a former 2020 agreement with certain entities of health care royalty. Our cash runway now reaches well into the third quarter of 2026, carrying us through key value-generating milestones such as Phase II REZPEG data in atopic dermatitis and alopecia areata. For the full year of 2024, we expect revenue between $75 million and $85 million, which includes $55 million to $65 million in noncash royalties along with $20 million to $25 million in product sales; full year R&D expense should land somewhere between $120 million and $130 million; that figure includes roughly $5 million to $10 million of noncash depreciation and stock-based compensation expense. The rise in R&D spend for 2024 compared with 2023 reflects greater investment in the REZPEG Phase IIb studies for atopic dermatitis and alopecia areata, plus IND-enabling studies for our antibody program, NKTR-0165. That increase gets partially offset by reduced spending on NKTR-255 clinical studies in cell therapy, which wrap up during 2024. The remaining going clinical studies for NKTR-255 are mostly funded through our external partners. For the entire 2024 year, we're anticipating G&A costs to land somewhere in the range of $70 million to $75 million, and that figure accounts for $5 million to $10 million in noncash depreciation along with stock-based compensation expense. When it comes to noncash interest expense across the full year, we're looking at somewhere between $20 million and $25 million. As I mentioned before, our expectation is to close out this year holding $200 million to $225 million in cash and investments. With all of that said, we're ready to take questions now. Crystal?
Cheng Li
analystThis is Cheng calling in for Jay. Congratulations on how things are moving forward. Perhaps regarding our REZPEG AD study — I was wondering whether you could discuss what doctors and patients taking part have said so far, particularly given that lots of other trials are competing in this space. Also, if you could say something about how enrollment has been going compared with what you expected internally, that would be wonderful. Then I have one brief follow-up.
Howard Robin
executiveMary, would you like to handle that?
Mary Tagliaferri
executiveAbsolutely, Howard. Thanks for that. Joe, it's Mary Tagliaferri here. If you take everything together — what we're seeing across site activation, screening, and enrollment — we remain on schedule to report top line induction data from the AD study during the first half of 2025. As far as the feedback goes, the screening we're observing has us quite encouraged, and our sense is that this traces back to data Jonathan Silverberg presented at the ADV 2023. Physicians genuinely recognize a few things: first, REZPEG shows an onset of action that is very rapid. Second, there's the depth of response we observe in the mean percent change in EASI following just 12 weeks of treatment, whereas the majority of studies examine an induction period of 16 weeks — that has left doctors quite impressed. And then, of course, for the <<inaudible>> their patients, the durability we saw when patients went off treatment for 9 consecutive months is something they truly appreciate. They could hold onto that highly important EASI response; all of this makes patient recruitment for the study very, very appealing. So things are going quite well. I've been told our studies are <<inaudible>> with enrollment, and that isn't happening to us.
Cheng Li
analystUnderstood. One more brief question. I'm curious how much the clinical infrastructure from the AD trial can carry over when you begin the alopecia areata program. Is it possible to simply rely on the same sites, or does additional work remain?
Mary Tagliaferri
executiveCorrect. For our alopecia study, we'll draw on 12 sites already taking part in the AD study, and those doctors are quite enthusiastic about the chance to assess REZPEG in a second skin condition, alopecia areata. Once more, they're genuinely keen to observe how long responses last, since their patients on JAK inhibitors regrow hair right away, then begin shedding it as soon as they stop the JAK inhibitor. So the potential of this agent <<inaudible>> and restoring immune privilege is certainly very heartening, and I'm thrilled to be discussing it.
Kambiz Yazdi
analystKambiz here, sitting in for Roger. I wanted to pick up where we left off regarding the alopecia areata trial — what's the overall count of clinical locations you plan to use for enrollment? Also, how are those locations spread out geographically? Beyond that, could you share the main baseline features expected among participants in these trials — will the majority be refractory to JAK inhibitors? Any specifics on that would be helpful.
Mary Tagliaferri
executiveSure. Thank you, Howard. We're looking at a bit more than 3 locations; our footprint will include Canada, the United States, and Poland. As you can probably guess, access is certainly a challenge in Poland, and getting those patients in front of a dermatologist takes quite a long time. That actually makes it a really good setting for bringing patients in. The patients we're targeting will not have prior JAK inhibitor exposure, and the primary requirement for entry is severe to very severe alopecia. Every one of these patients must have a SALT score driven with venereal and, naturally, this matches the same population where Lilis JAK, the JAK inhibitor from Pfizer, applies identical eligibility standards for its pivotal studies.
Jessica Fye
analystRegarding the Phase IIb atopic derm study, what level of improvement does a patient need to hit to count as a responder and then get rerandomized for IL-15? Also, I'd like to know your most recent thinking on which will report first — the AD trial or the alopecia trial — and what's behind that?
Mary Tagliaferri
executiveYes. Jessica, this is Mary; for someone to be re-randomized, that patient must achieve EASI-50 at the point they are rerandomized to the maintenance dose given once a month or once every 3 months, and they'll receive the same dose they had been randomized to during induction. And was there a second question from you?
Jessica Fye
analystIs it only a question of when the alopecia data comes relative to the AD data?
Mary Tagliaferri
executiveThat's right. So the readout we're expecting to see first is the <<inaudible>> trial.
Julian Harrison
analystI'd like to hear again how you're viewing effectiveness past 12 weeks of REZPEG treatment in atopic derm. Should we anticipate a plateau eventually? Or might response rates continue climbing across 44 weeks of dosing? Then, about the Lilly litigation — apologies if this was already covered — could you share where things stand now and when the next steps are expected?
Howard Robin
executiveMary, please handle the first question, and I'll address the second one.
Mary Tagliaferri
executiveAbsolutely. I really do believe that when we move the production timeline out from 12 weeks to 16 weeks, a larger group of patients is going to have a more profound response. So I'm quite eager to find out where the mean percent changes land. Our mean percent change in EASI from baseline out to 12 weeks, as you're aware, came in at 83%. That figure is higher than what we see with any of the biologics—whether you're looking at DUPI, ADBRY, Lebri, Nemo, or Roca—so we clearly observed the most profound response. Even so, my belief is that we will likely find additional patients reaching EASI-75 and even 90 once we add those extra 4 weeks onto the induction period.
Howard Robin
executiveSo, on the Lilly situation. After we filed our complaint in the federal courts, Lilly attempted to persuade the Federal Court judge who has missed the case, as you know. And last week, the federal judge refused Lilly's request. The judge also agreed to allow Nektar's claims, primary claims to move forward, and we expect the judge to settle trial date in 2025. The court also order the parties to engage in mediation within the next 3 months to try to resolve the issue. And so we're very, very happy with the case is moving forward. The judge did not dismiss the case; and we look forward to vindicating ourselves through the litigation process.
Andy Shah
analystWe have a couple of fast questions. First, could you address that back-and-forth pattern tied to shedding in alopecia — if we enroll people whose cases are severe and very severe, would that reduce the inconsistency? And question two concerns the TNF-receptor 165 program; we understand the receptor family forms a trimer. So I suppose that to achieve maximal agonism of this receptor, a trimer design might be necessary. I'm just wondering whether that is among the design elements incorporated into 165; and further along that line, clustering also comes into play; so does the molecule's design include that as well? Thanks.
Howard Robin
executiveMary, would you handle the hair loss, and then JZ can cover the TNFR2.
Mary Tagliaferri
executiveMary here, Andy. You've got it exactly right. When patients reach the severe stage and the very severe stage, as a general rule, hair does not grow back. And you're spot on that this is precisely why the eligibility criteria — and even the threshold the FDA uses for approval — center on this patient population. It's true that patients do begin by experiencing patchy hair loss. Yet as the disease advances, certainly, the hair loss becomes more extreme, and even moves toward baldness. But once a patient moves their hair. It's very <<inaudible>> to have regrowth their hair without some sort of medical intervention. Then I'll hand the second question over to JZ.
Jonathan Zalevsky
executiveAbsolutely, and thank you, Mary, and thank you, Andy, for asking that. You've got it right. So TNF proteins, or trimers—but as our knowledge has grown regarding the biophysics of these receptors and how the plat domains function, right, those stride domains that bind the receptor subunits together, they actually serve to form dimer receptors. Then a trimer arrives and clusters 6 receptors, or 3 pairs of dimers. So then further clustering can occur, and a portion of this ultrastructure has appeared in publications; structural investigations have also been carried out. What we've arrived at understanding, first, by studying the cell biology of these receptors—how these dimers must multimerize and how the epitopes for receptor binding must operate—is that the epitope holds fundamental importance. And something we found with NKTR-0165 is that its epitope possesses distinctive characteristics of its own, capable of signaling in a manner entirely independent of clustering. To illustrate, Fc isn't required. Balancing isn't required either; that's among the aspects that are truly unique and strongly differentiated in the antibodies we have developed. And bear in mind all these ultrastructural configurations of the receptor. And the various states the receptor may take on is clearly among the crucial factors for generating a successful activity. I appreciate the question.
Howard Robin
executiveAlright, thanks to each of you for being here today. And like we mentioned during our call, our attention continues to be squarely on moving forward with REZPEG’s development along with the research programs centered on immunology. I want to express appreciation to every one of our team members for putting in such diligent effort, and also to all holders of our stock, whether you’ve recently come aboard or been with us already, for sticking with us. We’re eager to bring you news about how things are advancing, so keep watching. Appreciate you all for tuning in once more.
Operator
operatorAppreciate it. That brings us to the end of today's call. We're grateful that you joined us. You're free to hang up at this point. Wishing each of you a great rest of your day.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Nektar Therapeutics transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.
Get the API View API docs →This call discussed
For developers and AI pipelines
Programmatic access to Nektar Therapeutics earnings transcripts and 132,000+ others is available through the
EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.
More tools for stock research
OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Nektar Therapeutics or any ticker on your watchlist.
StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.